Literature DB >> 21674564

Hairy cell leukaemia: biological and clinical overview from immunogenetic insights.

Francesco Forconi1.   

Abstract

Hairy cell Leukaemia (HCL) is a rare neoplasm of peripheral B cells which represents a paradox in oncology. Despite its largely unknown origin and behaviour, HCL is one of the few example of dramatic success in the treatment of a malignancy. The recent steps forward to understanding the biology of HCL from immunogenetic and genomic studies have recently provided new insight into diagnosis and prognosis. Several data from immunoglobulin gene (IG) analysis have provided hints regarding the cell of origin and the ongoing selective interactions of the tumour BCR with environmental stimuli. It has also recently emerged that an unmutated status of the HCL IG can be associated with failure to respond to cladribine, genetic abnormalities indicative of poor outcome and aggressive disease. These observations suggest a central role of the tumour B-cell receptor in defining the outcome of HCL and that that IG gene analysis may have biological and prognostic relevance. Hopefully, IG analysis will help tailor treatment strategies for the most aggressive cases.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21674564     DOI: 10.1002/hon.975

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  9 in total

Review 1.  Hairy cell leukemia: present and future directions.

Authors:  Robert J Kreitman
Journal:  Leuk Lymphoma       Date:  2019-05-09

2.  Massive splenomegaly.

Authors:  Hugo L Paz-Y-Mar; Alexei Gonzalez-Estrada; M Chadi Alraies
Journal:  BMJ Case Rep       Date:  2013-07-29

Review 3.  The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets.

Authors:  Jan A Burger; Mariela Sivina; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2011-03-25

Review 4.  Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.

Authors:  Jérôme Paillassa; Firas Safa; Xavier Troussard
Journal:  Ther Adv Hematol       Date:  2022-04-13

5.  Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method.

Authors:  Hidekazu Itamura; Masaru Ide; Akemi Sato; Naoko Sueoka-Aragane; Eisaburo Sueoka; Aya Nishida; Taro Masunari; Sadao Aoki; Jun Takizawa; Junji Suzumiya; Shinya Kimura
Journal:  Int J Hematol       Date:  2018-07-24       Impact factor: 2.490

6.  The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.

Authors:  Mariela Sivina; Robert J Kreitman; Evgeny Arons; Farhad Ravandi; Jan A Burger
Journal:  Br J Haematol       Date:  2014-04-02       Impact factor: 6.998

7.  Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion.

Authors:  Nicola J Weston-Bell; Will Tapper; Jane Gibson; Dean Bryant; Yurany Moreno; Melford John; Sarah Ennis; Hanneke C Kluin-Nelemans; Andrew R Collins; Surinder S Sahota
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

8.  Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes.

Authors:  Nicola J Weston-Bell; Francesco Forconi; Hanneke C Kluin-Nelemans; Surinder S Sahota
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

9.  Hairy cell leukemia: short review, today's recommendations and outlook.

Authors:  V Maevis; U Mey; G Schmidt-Wolf; I G H Schmidt-Wolf
Journal:  Blood Cancer J       Date:  2014-02-14       Impact factor: 11.037

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.